Osiris Therapeutics, Inc. (NASDAQ: OSIR), today announced that it has successfully completed enrollment in a Phase 2 clinical trial evaluating Prochymal (remestemcel-L), an adult mesenchymal stem cell therapy, in patients experiencing their first heart attack. The double-blind, placebo-controlled trial enrolled a total of 220 patients from 33 leading clinical centers in the United States and Canada.
"We appreciate the participation of our outstanding team of clinicians and would like to offer our special thanks to the patients who are taking part in this exciting trial," said Lode Debrabandere, Ph.D., Senior Vice President of Therapeutics at Osiris. "We look forward to following their progress and collecting high quality data on the safety and efficacy of Prochymal in this significant indication."
In 2009, Osiris completed a Phase 1 double-blind, placebo-controlled study in 53 patients that demonstrated the safety of Prochymal in cardiac patients suffering from their first heart attack. Additionally, treatment with Prochymal significantly improved cardiac function, patient global assessment and reduced cardiac arrhythmias (irregular heartbeat) when compared to placebo.
Decoding the genetic roots of stroke and heart attack